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Introduction
Almost more than a decade, Cardiac Re-synchronization Therapy (CRT) has been accepted as an effective therapy for heart failure (HF) patients with reduced left 
ventricle ejection fraction (LVEF) and wide QRS 
complex.1 There is a plethora of evidences which show 
the benefits of CRT in reduction of morbidity and 
mortality and improvement of quality of life.2,3 The 
CRT indication has also been extended to Implantable 
Cardioverter Defibrillator (ICD)-indicated patients 
and some landmark trials have notified the superiority 
of CRT with defibrillator (CRT-D) over ICD alone.4-6 
As the device development becomes more complicated, 
it definitely raises a cost issue, especially when incor-
porated with ICD (CRT-D).
Unfortunately, there is a significant number of pa-
tients who do not response sufficiently (non-responders, 
NR) with average incidence of 30%7 and only 50% this 
group will survive at four years after implant.8 The ter-
minology of responder and non-responder is confused 
over outcome after CRT implant since the ability to 
predict which patient will benefit by how much is still 
limited.9 This problem needs to be addressed holistically 
so that the patients will gain the outmost benefit of this 
costly therapy.  However, there are dissimilar opinions 
with regards to definition and criteria used for this 
terminology. Response and outcome are not similar. 
What is very clear that non-responders are linear to pre-, 
peri-, and post-implant factors.10 The ability of timely 
identification of these components are essential for both 
implanting and referring physicians so that early correc-
tions could be carried out appropriately.
Which patients are considered non-
responders?
HF is a complex and dynamic process along its natural 
course and so is its response towards a therapy. Thus, 
the criteria of NR is not easy to define as it involves 
multifactorial components. Even, most of major 
CRT trials adopted different criteria for NR.11 From 
the patient’s and clinician’s perspective, alleviation of 
symptom (dyspnea) and reduction of re-hospitalization 
are essential especially for patients with New York 
Heart Association (NYHA) functional class III and 
IV. In summary, the parameters considered clinically 
practical are functional capacity and quality of life, 
mortality, and remodeling indicators (increment 
of ejection fraction, reduction in left ventricular 
dimension and LV end-systolic volume index).7,10,11
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Pre-implant: Appropriate patient 
selection
The strongest predictor for satisfactory outcome in 
CRT is ECG pattern of left bundle branch block 
(LBBB) with prolonged QRS duration (≥150 millisec-
ond) as proven by Auricchio, et al.12 In Comparison of 
Medical Therapy, Pacing, and Defibrillation in Heart 
Failure (COMPANION) trial, those without LBBB 
does not have significant clinical benefit and those with 
QRS duration ≤147 ms does not have any benefit at 
all.13 When multiple QRS cut- points were considered, 
male patients who received CRT-D benefited only 
when the QRS duration was at least 160 ms, although 
female patients benefited from CRT therapy across all 
QRS durations <180 ms.14
Although QRS duration recruited in trials ranged 
between 120 ms to 200 ms, the median is around 
150 ms. Thus, all recent international guidelines 
recommend to apply this simple criteria for patient 
selection and classified as Class Ia indication (strong 
recommendation).1,15 Strauss, et al16 proposed a better 
criteria for LBBB which includes QRS duration ≥140 
ms (men) or 130 ms (women), QS or rS in leads V1 
and V2, and mid-QRS notching or slurring in ≥2 of 
leads V1, V2, V5, V6, I, and aVL. Figure 1 represents 
a classical pattern of ECG for CRT and the patient 
responded very well three months after implant.
Other clinical variables (male gender, ischemic 
etiology, NYHA functional class IV) and echocar-
diographic parameters (severe mitral regurgitation, 
prominent LA dilatation, and short interventricular 
mechanical delay) are strongly related to poor out-
come.17 Presence of concomitant diseases, such as 
renal dysfunction and ischemia, will blunt the positive 
effect of CRT.10
Atrial Fibrillation (AF), dominantly permanent AF, 
is not uncommon in HF patients and it counts around 
25% of CRT population.18 The negative consequence 
of AF in CRT patient, especially if the intrinsic rate 
is very fast, is the sub-optimal percentage of captured 
biventricular pacing. Therefore, the indication of CRT 
in patients with AF, ejection fraction ≤35%, QRS 
duration ≥130 ms is set under class IIa.1 Interventional 
approach (AV nodal junction ablation) is reserved only 
when drugs fail to achieve sufficient ventricular rate. 
Peri-implant: Targeting the most 
delayed area (LV lead placement)
Appropriate LV lead placement remains challenging 
in CRT implant as the coronary sinus (CS) tributaries 
anatomy varies among individuals. However, in 
general, lateral or posterolateral position, and basal 
location is preferred as it linearly associates with 
positive response.19 These locations are considered 
the most delayed portions of LV; so that if being 
Figure 1. Pre-implant EKG of a patient who is considered super-responder. Note the LBBB pattern with 
QRS duration of 160 ms. rS pattern in V1, and QRS notching or slurring in V5-V6 and I-AVL.
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Figure 2. LV lead is placed at posterolateral branch of 
coronary sinus. The delay between onset of surface EKG and 
LV electrogram was noted around 170 ms (lower panel). It 
indicates that LV lead position is delayed enough and this 
patient gave significant response after three months.
paced in a synchronized passion, will increase cardiac 
output. Several non-invasive modalities (spectral 
echocardiography, electromechanical mapping) are 
being utilized to identify the most delayed part of LV 
as the target for pacing site. However, its adoption 
in routine clinical arena is time consuming and not 
practical. Moreover, spectral echocardiography was 
unable to differentiate outcome among patients with 
QRS duration ≥150 ms, but it was able to predict 
event in patients with QRS duration between 120 ms 
and 150 ms.20
During implant, distance between surface EKG 
and LV electrogram (>90ms) could be applied to 
recognize the presence of most delayed part of LV 
which correlates with reverse remodeling.21 Figure 
2 demonstrates example method of determining the 
most delayed part of LV from surface EKG and LV 
electrogram.
The commonest handicaps during LV lead implant 
are uncaptured site and the phrenic nerve stimulation. 
Multi-point pacing algorithm is currently available 
with beneficial evidence to overcome those problems.22 
Quadri-polar lead is also another option as it is able 
to span a larger area of myocardium and give us the 
ability to pace more hemodynamically and electrically 
beneficial sites.23
Post-implant: Optimal heart failure 
management and device follow-up
The complexity of HF pathogenesis requires a 
multidisciplinary approach which involves cardiac 
rehabilitation, education, and nutritionist. Drug 
therapy should be optimized as recommended by 
guidelines (guideline directed medical therapy, 
GDMT) which include ACE-inhibitor, Angiotensin-
Receptor blocker (ARB), diuretics, beta-blocker, 
aldosterone-antagonist, and digitalis.1  
Thus, GDMT is mandatory in HF management 
to help obtain the criteria of ‘responder’ for those 
who received CRT. Optimization of neuro-hormonal 
blockers is more important than diuretics as proven 
by Schmidt, et al.24
Post-implant programming is essential to prevent 
NR especially with regards to pacing mode, capture 
output, lower and upper rate, and AV-VV intervals and 
an observational study has proved that sub-optimal 
AV-VV delay as a meaningful factor of poor response.2 
The ESC guidelines recommend to first programmed a 
fixed 100 – 120 ms AV delay without VV interval. 25
Several potentially correctable causes (atrial 
fibrillation, premature ventricular contraction (PVC), 
secondary valvular heart disease, and ischemia) may 
co-exist in HF patients.  The co-existence of AF (see 
Figure 3) and PVC may reduce resynchronization 
pacing which worsen the outcome. 
Antiarrhythmic drugs (AAD) are indicated and 
Figure 3. Intermittent biventricular pacing (wide QRS 
complex) is induced by the presence of atrial fibrillation. 
This patient only got 86% of resynchronized pacing which 
was noted from the programmer counter (ideal percentage 
of pacing should be closed to 100%). 
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should be individualized to abolish the rhythm 
disorder. To some extent, catheter ablation may be a 
good treatment of option.
The presence of secondary valvular heart disease, 
especially mitral regurgitation (MR), is prevalent in 
HF patients. A study on interventional mitral-clip for 
severely symptomatic CRT non-responders, has noted 
that 70% of patients improved and showed reverse 
remodeling after 12 months.26 Another important 
issue that needs careful attention is the presence of 
ischemia in HF patients. Imaging modality such as 
MRI or perfusion test could predict the significance of 
ischemic area and viability assessment of left ventricle. 
If necessary, revascularization—either by percutaneous 
intervention or CABG—is advised to improve clinical 
response and reverse remodeling.
Conclusion
Non-responders remains a challenging issue in 
CRT population and requires a comprehensive 
understanding and multi-disciplinary approach to 
overcome. The preventive strategy should be applied 
from the patient selection phase with very meticulous 
criteria to achieve responders (wide QRS duration with 
LBBB morphology and non-ischemic etiology). To 
obtain maximum resynchronization, LV lead should 
be placed at the latest portion of LV (either by selection 
of posterolateral or lateral CS branch or by measuring 
the delay between surface ECG and LV EGM of more 
than 90 ms). Quadripolar or multi-site pacing may 
be utilized to optimize LV pacing sites. Post-implant 
follow-up is of outmost importance to solve some 
issues contributing to non-responders such as medical 
therapy escalation, arrhythmia abolition, and ischemia 
treatment. This holistic strategy should be exercised 
from time to time during follow-up to achieve most 





COMPANION: comparison of medical therapy, pacing, 
and defibrillation in heart failure
CRT: cardiac resynchronization therapy 
CRT-D: CRT with defibrillator
CS: coronary sinus 
GDMT: guideline directed medical therapy
HF: heart failure 
ICD: implantable cardioverter defibrillator
LBBB: bundle branch block
LVEF: left ventricle ejection fraction
NR: non-responders
NYHA: New York Heart Association
PVC: premature ventricular contraction
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